Sensydia Raises $8M Funding Round for Breakthrough Cardiac Assessment Platform

Non-invasive cardiac assessment firm Sensydia has raised about $8 million from an expanded syndicate of investors.
 
According to the company, proceeds will prepare Sensydia to prepare to commercialize its Cardiac Performance System (CPS) non-invasive cardiac assessment platform. The company is pushing the boundaries of its heart-sound artificial intelligence (AI) tech, which aims to transform diagnosis and management of heart disease.
 
“We are thrilled to have the support of investors who share our vision for transforming heart failure management,” Anthony Arnold, president and CEO of Sensydia told the press. “This funding will enable us to accelerate our march to commercialization by expanding development and operations for our CPS platform.”
 
The CPS platform utilizes ultra-sensitive biosensors and AI algorithms to rapidly and non-invasively measure ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure in a handheld device—without the need for in-hospital catheterization.
 
The funding was led by Florida-based Orlando Health Ventures, with participation from Colle Capital, Frontier Venture Capital, and others.
 
“Sensydia’s CPS technology is a game-changing AI application that makes crucial cardiac data both accessible and affordable,” said Victoria Grace, founder of Colle Capital and Sensydia board member. “This technology transcends geographical and financial barriers to care, unlocking new markets while enhancing early diagnosis and treatment protocols.”
 
“Non-invasive and real-time cardiac function measures will lead to early diagnosis and personalized care for heart disease,” added Farhan Khawaja, MD, president of the Orlando Health Heart & Vascular Institute. “This technology has the potential to vastly improve patient lives by enabling faster and more affordable disease management, moving healthcare from the hospital setting into the patient’s home.”
 
The funding enables Sensydia to finalize CPS platform development and submit to the U.S. Food and Drug Administration (FDA) in 2024 for prioritized review. The CPS platform achieved FDA breakthrough device status in 2022.
 
Sensydia also released results of a 225-subject study using the CPS platform in March.